E
E. Kaukel
Researcher at University of Texas MD Anderson Cancer Center
Publications - 26
Citations - 5659
E. Kaukel is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Carboplatin & Chemotherapy. The author has an hindex of 14, co-authored 25 publications receiving 5363 citations.
Papers
More filters
Journal ArticleDOI
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Nicholas J. Vogelzang,James J. Rusthoven,James T. Symanowski,Claude Denham,E. Kaukel,Pierre Ruffié,Ulrich Gatzemeier,Michael Boyer,Salih Emri,Christian Manegold,Clet Niyikiza,Paolo Paoletti +11 more
TL;DR: Treatment with pemetrexed plus cisplatin and vitamin supplementation resulted in superior survival time, time to progression, and response rates compared with treatment with cis Platin alone in patients with malignant pleural mesothelioma.
Journal ArticleDOI
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
Frank V. Fossella,José Rodrigues Pereira,Joachim von Pawel,Anna Pluzanska,Vera Gorbounova,E. Kaukel,K. Mattson,Rodryg Ramlau,Aleksandra Szczesna,Panagiotis Fidias,Michael Millward,Chandra P. Belani +11 more
TL;DR: DC resulted in a more favorable overall response and survival rate than VC, demonstrating that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
Journal ArticleDOI
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
Ulrich Gatzemeier,Anna Pluzanska,Aleksandra Szczesna,E. Kaukel,Jaromír Roubec,Flavio De Rosa,Janusz Milanowski,Hanna Karnicka-Mlodkowski,Miloš Pešek,Piotr Serwatowski,Rodryg Ramlau,Terezie Janaskova,Johan Vansteenkiste,János Strausz,Georgy M. Manikhas,Joachim von Pawel +15 more
TL;DR: Erlotinib with concurrent cisplatin and gemcitabine showed no survival benefit compared with chemotherapy alone in patients with chemotherapy-naïve advanced NSCLC.
Journal ArticleDOI
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
U. Gatzemeier,Anna Pluzanska,Aleksandra Szczesna,E. Kaukel,Jaromír Roubec,U. Brennscheidt,F. de Rosa,B. Mueller,J. von Pawel +8 more
TL;DR: TALENT was a placebo-controlled study in patients with previously untreated advanced NSCLC to receive erlotinib at 150mg/d or placebo (PBO) with 6 cycles of gemcitabine and cisplatin followed by monotherapy, with primary endpoint duration of survival.
Journal ArticleDOI
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
Luis Paz-Ares,Helen J. Ross,Mary O'Brien,A. Riviere,U. Gatzemeier,J. von Pawel,E. Kaukel,Lutz Freitag,W. Digel,Helge Bischoff,R García-Campelo,N Iannotti,P. Reiterer,Isabel Bover,J Prendiville,Amy J. Eisenfeld,Fred B. Oldham,B. Bandstra,Jack W. Singer,Philip Bonomi +19 more
TL;DR: Compared with docetaxel, PPX had less febrile neutropenia and less alopecia, shorter infusion times, and elimination of routine use of medications to prevent hypersensitivity reactions.